Daniel Welch

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Part of GSK Plc, Sterling Winthrop, Inc. is a company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million.

Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA.

Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.

Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL.

Levo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Glenview, IL.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.